Celltrion USA said that it reached an agreement with Express Scripts. The agreement provides ZYMFENTRA Preferred Brand Access on the Express Scripts National Preferred Formulary serving 21.9 Million insured lives.
Express Scripts provides plan participants such as Health Plans of the PBM the ability to add ZYMFENTRA or infliximab-dyyb to their formularies.
Celltrion's ZYMFENTRA, the first and only FDA-approved subcutaneous infliximab, is now commercially available in the U.S.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.